SCHEMBL1576548

SCHEMBL1576548

Cc1ccc(NC(=O)N2CC(N(CCO)CCO)C2)cc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.51
NPC1 O15118 4/20 0.51
TAS1R3 Q7RTX0 2/20 0.49
TAS1R1 Q7RTX1 2/20 0.49
TAS1R2 Q8TE23 2/20 0.49
NAMPT P43490 1/20 0.49
GRIN2B Q13224 4/20 0.48
TSHR P16473 2/20 0.48
FAAH O00519 1/20 0.46
MAPT P10636 3/20 0.45
PAX8 Q06710 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 2/20 0.44
TP53 P04637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 1/20 0.44
KDM4E B2RXH2 1/20 0.44
GFER P55789 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575232 0.89 NPC1 (0.51) RAB9ANPC1TAS1R3TAS1R1TAS1R2
SCHEMBL1574631 0.86 MAPT (0.46) RAB9ANPC1GRIN2BTSHRMAPT
SCHEMBL1574671 0.86 ALOX5 (0.54) RAB9ANPC1TAS1R3TAS1R1TAS1R2
SCHEMBL1574821 0.86 KMT2A (0.51) RAB9ANPC1GRIN2BMAPTPAX8
SCHEMBL1575584 0.86 GRIN2B (0.51) RAB9ANPC1GRIN2BFAAHMAPT
SCHEMBL1574617 0.86 NPC1 (0.54) RAB9ANPC1TAS1R3TAS1R1TAS1R2
SCHEMBL1574531 0.86 MAPT (0.58) RAB9ANPC1TAS1R3TAS1R1TAS1R2
SCHEMBL1574442 0.86 NPC1 (0.52) RAB9ANPC1FAAHMAPTSMN1; SMN2
SCHEMBL1575130 0.86 NPC1 (0.54) RAB9ANPC1TSHRMAPTSMN1; SMN2
SCHEMBL1574656 0.85 ALDH1A1 (0.56) RAB9AGRIN2BFAAHMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB RAB9A 898/4885NPC1 413/4885TAS1R3 4140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.